Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

XENE

Xenon Pharmaceuticals Inc

Sep 20 • 04:00PM ET

40.15

Dollar change -0.64
Percentage change -1.57	%

Healthcare • Biotechnology • Canada • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IBB VHT SPDW SBIO ESML VT FHLC SMMV ONEQ PRFZ

Index	-	P/E	-	EPS (ttm)	-2.74	Insider Own	2.56%	Shs Outstand	75.37M	Perf Week	-1.69%
Market Cap	3.04B	Forward P/E	-	EPS next Y	-3.59	Insider Trans	0.00%	Shs Float	73.82M	Perf Month	2.58%
Income	-199.06M	PEG	-	EPS next Q	-0.83	Inst Own	96.53%	Short Float	4.84%	Perf Quarter	7.10%
Sales	0.00M	P/S	-	EPS this Y	-14.34%	Inst Trans	1.08%	Short Ratio	8.79	Perf Half Y	-7.59%
Book/sh	11.15	P/B	3.60	EPS next Y	-15.06%	ROA	-25.38%	Short Interest	3.57M	Perf Year	12.03%
Cash/sh	9.52	P/C	4.22	EPS next 5Y	8.90%	ROE	-26.71%	52W Range	27.99 - 50.99	Perf YTD	-12.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.87%	ROI	-23.34%	52W High	-21.26%	Beta	1.25
Dividend TTM	-	Quick Ratio	23.27	Sales past 5Y	35.90%	Gross Margin	-	52W Low	43.47%	ATR (14)	1.42
Dividend Ex-Date	-	Current Ratio	23.27	EPS Y/Y TTM	-9.82%	Oper. Margin	0.00%	RSI (14)	50.99	Volatility	3.24% 3.31%
Employees	259	Debt/Eq	0.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.07	Target Price	58.15
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-3.50%	Payout	-	Rel Volume	0.77	Prev Close	40.79
Sales Surprise	-	EPS Surprise	-7.11%	Sales Q/Q	-	Earnings	Aug 08 AMC	Avg Volume	405.87K	Price	40.15
SMA20	0.60%	SMA50	-1.79%	SMA200	-4.63%	Trades		Volume	311,468	Change	-1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-24	Initiated	Citigroup	Buy	$62
Dec-08-23	Initiated	Robert W. Baird	Outperform	$63
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight	$58
Dec-14-22	Initiated	Goldman	Buy	$60
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight	$50
Oct-19-22	Initiated	Raymond James	Outperform	$52
Aug-29-22	Initiated	BofA Securities	Buy	$45
Jul-21-22	Initiated	JP Morgan	Overweight	$55
Oct-28-21	Initiated	RBC Capital Mkts	Outperform	$43
Oct-02-20	Initiated	SVB Leerink	Outperform	$22
Jul-21-20	Initiated	Needham	Buy	$22
Jun-01-20	Resumed	Jefferies	Buy	$23
Mar-25-20	Initiated	Wedbush	Outperform	$23
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy	$25
Aug-08-18	Reiterated	Stifel	Buy	$9 → $15
Mar-13-17	Initiated	Jefferies	Buy	$13
Oct-21-16	Initiated	Stifel	Buy	$18

Show Previous Ratings

Sep-09-24 08:30AM	Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress (GlobeNewswire)
Sep-05-24 01:12AM	Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-21-24 10:46AM	Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe (Zacks)
Aug-12-24 08:30AM	Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer (GlobeNewswire)
10:19AM	Loading…
Aug-09-24 10:19AM	Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down (Zacks)
Aug-08-24 09:59PM	XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:26PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q2 2024 Financial Results and Business Update (GlobeNewswire)
Aug-01-24 04:01PM	Xenon to Report Q2 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jun-27-24 03:54PM	Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50? (Insider Monkey)
Jun-05-24 04:01PM	Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 08:30AM	Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting (GlobeNewswire)
May-27-24 06:55PM	Hedge Funds are Racking Up Shares of This Healthcare Stock (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
05:03PM	Loading…
May-10-24 05:03PM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:56PM	Xenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ... (GuruFocus.com)
08:17AM	Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus (Zacks)
07:29AM	Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating (MT Newswires)
May-09-24 08:57PM	XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:29PM	Xenon Pharmaceuticals Q1 Net Loss Narrows (MT Newswires)
04:17PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 04:01PM	Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024 (GlobeNewswire)
May-07-24 04:01PM	Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-06-24 12:00PM	What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock (Zacks)
May-02-24 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-16-24 08:30AM	Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 08:30AM	Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-04-24 04:01PM	Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Mar-12-24 04:01PM	Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-08-24 11:55PM	Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ... (GuruFocus.com)
Mar-05-24 04:01PM	Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Mar-02-24 08:37AM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 08:35AM	Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus (Zacks)
Feb-29-24 04:34PM	Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:13PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-22-24 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Feb-21-24 10:08PM	3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
Jan-23-24 08:36AM	Here's Why You Should Add Xenon (XENE) to Your Portfolio Now (Zacks)
Jan-19-24 09:55AM	Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet (Zacks)
Jan-08-24 08:00AM	Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 (GlobeNewswire) +5.23%
Jan-03-24 08:30AM	Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 01:31PM	5 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
Dec-04-23 04:16PM	Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-02-23 12:01PM	Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) (GlobeNewswire)
Nov-29-23 10:51PM	Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering (GlobeNewswire) +8.39%
04:03PM	Xenon Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Nov-28-23 11:17AM	Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study (Zacks)
Nov-27-23 04:28PM	The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring (Investor's Business Daily) +17.78%
12:19PM	Cerence, Roivant Sciences fall; Xenon Pharmaceuticals, Shopify rise, Monday, 11/27/2023 (Associated Press Finance)
07:30AM	UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study (Reuters)
07:09AM	Xenon Pharmaceuticals' depression drug fails to meet main goal in study (Reuters)
07:00AM	Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD) (GlobeNewswire)
04:21AM	Xenon drug misses main goal of depression study (BioPharma Dive)
Nov-09-23 05:14PM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript (Insider Monkey) -6.69%
04:03PM	Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences (GlobeNewswire)
Nov-08-23 04:28PM	Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire) +5.93%
Oct-31-23 02:58AM	13 Best Canadian Stocks to Buy and Hold (Insider Monkey)
Oct-09-23 04:15PM	Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b X-TOLE Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology (GlobeNewswire)
Oct-06-23 08:30AM	Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire)
Sep-14-23 04:01PM	Xenon Pharmaceuticals to Present at TD Cowens 3rd Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Sep-12-23 04:30PM	Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder (GlobeNewswire)
Sep-04-23 08:30AM	Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress (GlobeNewswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey)
04:01PM	Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference (GlobeNewswire)
Aug-29-23 10:21AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
Aug-11-23 09:55AM	Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade (Zacks)
Aug-09-23 05:15PM	Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.29%
04:09PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
04:01PM	Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:03AM	Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-08-23 04:01PM	Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover (GlobeNewswire)
Aug-02-23 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jul-23-23 11:44AM	11 Best Healthcare Stocks Under $50 (Insider Monkey)
Jun-06-23 04:35PM	Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-31-23 04:01PM	Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-09-23 05:15PM	Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.51%
04:13PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
04:01PM	Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-23 10:00AM	Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline (Zacks)
03:52AM	Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
May-03-23 04:01PM	Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023 (GlobeNewswire)
May-02-23 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
10:01AM	Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-24-23 08:00AM	Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire)
Apr-21-23 04:01PM	Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-18-23 08:15AM	Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-22-23 04:01PM	Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days (GlobeNewswire)
Mar-06-23 01:07AM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 07:48AM	Xenon Pharmaceuticals Full Year 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Mar-02-23 05:31AM	We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth (Simply Wall St.) -7.39%
Mar-01-23 05:25PM	Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-22-23 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update (GlobeNewswire)
Feb-08-23 04:01PM	Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GAROFALO ELIZABETH A.	Director	Mar 08 '24	Option Exercise	18.56	3,500	64,960	3,500	Mar 11 08:09 PM
GAROFALO ELIZABETH A.	Director	Mar 08 '24	Sale	45.69	2,092	95,583	0	Mar 11 08:09 PM
ROBIN SHERRINGTON	EVP, Strategy & Innovation	Mar 07 '24	Option Exercise	9.85	8,641	85,114	16,824	Mar 08 05:31 PM
ROBIN SHERRINGTON	EVP, Strategy & Innovation	Mar 07 '24	Sale	46.28	7,137	330,290	8,398	Mar 08 05:31 PM
GANNON STEVEN	Director	Mar 07 '24	Sale	46.28	13,000	601,615	2,000	Mar 08 05:28 PM
AZAB MOHAMMAD	Director	Dec 19 '23	Option Exercise	9.85	4,320	42,552	74,225	Dec 20 05:04 PM
PATOU GARY	Director	Dec 13 '23	Option Exercise	9.55	14,402	137,487	29,951	Dec 15 05:38 PM
PATOU GARY	Director	Dec 13 '23	Sale	39.29	11,380	447,085	23,573	Dec 15 05:38 PM
PATOU GARY	Director	Dec 13 '23	Sale	41.05	7,598	311,898	4,902	Dec 15 05:38 PM

Open in Screener

SLRN

Acelyrin Inc

Sep 20 • 04:00PM ET

5.39

Dollar change +0.09
Percentage change 1.70	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VB IWN VBK IBB VXF VTWO IWC SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.06	Insider Own	35.41%	Shs Outstand	97.87M	Perf Week	14.68%
Market Cap	537.98M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	-0.03%	Shs Float	64.46M	Perf Month	12.29%
Income	-299.80M	PEG	-	EPS next Q	-0.80	Inst Own	77.37%	Short Float	11.16%	Perf Quarter	32.11%
Sales	0.00M	P/S	-	EPS this Y	45.60%	Inst Trans	-	Short Ratio	6.28	Perf Half Y	-30.72%
Book/sh	5.71	P/B	0.94	EPS next Y	28.97%	ROA	-40.33%	Short Interest	7.20M	Perf Year	-45.28%
Cash/sh	6.36	P/C	0.85	EPS next 5Y	-	ROE	-43.79%	52W Range	3.36 - 10.70	Perf YTD	-27.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-52.66%	52W High	-49.65%	Beta	2.29
Dividend TTM	-	Quick Ratio	7.86	Sales past 5Y	0.00%	Gross Margin	-	52W Low	60.42%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	7.86	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	59.10	Volatility	10.31% 8.17%
Employees	130	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.86	Target Price	11.40
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-222.51%	Payout	-	Rel Volume	2.85	Prev Close	5.30
Sales Surprise	-	EPS Surprise	-10.26%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	1.15M	Price	5.39
SMA20	14.01%	SMA50	2.02%	SMA200	-9.42%	Trades		Volume	3,268,593	Change	1.70%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$18 → $6
Jul-08-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$13
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Sep-19-24 07:00AM	ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 (GlobeNewswire) +15.22%
Sep-12-24 01:30AM	Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc (GuruFocus.com)
Sep-10-24 07:00AM	ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery (GlobeNewswire)
Aug-22-24 07:00AM	ACELYRIN, INC. to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.42%
Aug-13-24 04:00PM	ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results (GlobeNewswire) -14.71%
03:37AM	Loading…
03:37AM	Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now? (Insider Monkey)
Aug-06-24 04:30PM	ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 (GlobeNewswire)
May-29-24 07:00AM	ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 (GlobeNewswire)
May-15-24 11:54AM	SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:01AM	ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Leadership Transition (GlobeNewswire)
Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
04:01PM	Loading…
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire) +10.89%
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
09:25PM	Loading…
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire) +8.51%
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41% +8.16%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com) -8.70%
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire) -10.36%
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire) -54.12%
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Becker Daniel J.	Director	Jul 17 '24	Sale	6.86	1	7	2,999	Jul 19 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Apr 01 '24	Sale	6.63	9,961	66,024	1,577,374	Apr 03 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Feb 20 '24	Sale	7.60	15,701	119,403	1,587,335	Feb 22 07:04 PM
Lin Shao-Lee	Chief Executive Officer	Jan 02 '24	Sale	7.41	10,691	79,188	1,603,036	Jan 04 06:09 PM

XENE

Xenon Pharmaceuticals Inc

SLRN

Acelyrin Inc

Upgrade your FINVIZ experience